GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AXIM Biotechnologies Inc (OTCPK:AXIM) » Definitions » Debt-to-EBITDA
中文

AXIM Biotechnologies (AXIM Biotechnologies) Debt-to-EBITDA : -0.93 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is AXIM Biotechnologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

AXIM Biotechnologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.10 Mil. AXIM Biotechnologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.80 Mil. AXIM Biotechnologies's annualized EBITDA for the quarter that ended in Dec. 2023 was $-6.36 Mil. AXIM Biotechnologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.93.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for AXIM Biotechnologies's Debt-to-EBITDA or its related term are showing as below:

AXIM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.08   Med: -1.1   Max: -0.15
Current: -0.92

During the past 13 years, the highest Debt-to-EBITDA Ratio of AXIM Biotechnologies was -0.15. The lowest was -2.08. And the median was -1.10.

AXIM's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs AXIM: -0.92

AXIM Biotechnologies Debt-to-EBITDA Historical Data

The historical data trend for AXIM Biotechnologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AXIM Biotechnologies Debt-to-EBITDA Chart

AXIM Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.90 -1.06 -0.50 -1.44 -0.92

AXIM Biotechnologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.09 -0.52 -0.51 2.64 -0.93

Competitive Comparison of AXIM Biotechnologies's Debt-to-EBITDA

For the Biotechnology subindustry, AXIM Biotechnologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AXIM Biotechnologies's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's Debt-to-EBITDA falls into.



AXIM Biotechnologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

AXIM Biotechnologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.095 + 5.8) / -6.428
=-0.92

AXIM Biotechnologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.095 + 5.8) / -6.364
=-0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


AXIM Biotechnologies  (OTCPK:AXIM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


AXIM Biotechnologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AXIM Biotechnologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


AXIM Biotechnologies (AXIM Biotechnologies) Business Description

Traded in Other Exchanges
N/A
Address
6191 Cornerstone Court, E, Suite 114, San Diego, CA, USA, 92121
Axim Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, it owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications.
Executives
Kurt Phinney officer: Chief Operating Officer 6914 MAGELLAN WAY, SARASOTA FL 34243
Peter O'rourke director C/O NORTHVIEW ACQUISITION CORP., 207 WEST 25TH STREET, 9TH FLOOR, NEW YORK NY 10001
Catalina Valencia 10 percent owner 6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Glycodots, Llc 10 percent owner 6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Juniper & Ivy Corp 10 percent owner 5201 MEMORIAL DRIVE, SUITE 616, HOUSTON TX 77007
Huemoeller John Walter Ii director 305 SAN ANSELMO AVENUE, SUITE 300, SAN ANSELMO CA 94960
Blake Schroeder director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert L Cunningham director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Timothy Richard Scott director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert Malasek officer: CFO PO BOX 235472, ENCINITAS CA 92023
Lekhram Changoer 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Medical Marijuana, Inc. 10 percent owner 12255 CROSTHWAITE CIRCLE, POWAY CA 92064
Van Damme Philip A 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Foundation Sanammad 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
George Anastassov 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022

AXIM Biotechnologies (AXIM Biotechnologies) Headlines

From GuruFocus